tirzepatide trial results SURMOUNT-2: confers about 15% weight loss in adults with obesity and diabetes FDA Approves Tirzepatide, A Potential
Description
Lilly announced the topline results from its phase 3b "TOGETHER PsA" trial, showing that the combination use of ixekizumab (Taltz) and tirzepatide (Zepbound) was superior to IXE alone, yielding both significant weight loss and ACR50 disease control in adults with active psoriatic arthritis (PsA).
Tirzepatide details covers drugs, mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details
Struggling with ineffective diets, workouts
Therapeutic Advances in Endocrinology and Metabolism, 6(1), 19-28
